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INTRODUCTION
Menopause constitutes a critical time in a woman's life, defining the end of her reproductive years and the onset of various metabolic changes, due mainly to the loss of estrogens. 1, 2 In postmenopausal women, remodelling of body composition take place, i.e. qualitative and quantitative changes in fat, muscle and bone mass, accompanied by emotional and psychological problems; 3, 4 these changes appear to mediate menopause-related metabolic and cardiovascular morbidity and mortality. 1, 2, 5 Increased total fat mass, trunk fat accumulation and decreased peripheral fat deposition as well as ectopic fat storage are observed and are often associated with adverse health consequences. [5] [6] [7] In addition, the loss of muscle mass-defined as sarcopenia-in the postmenopausal period and in later life is associated with metabolic dysregulation. 6 Hence, the detailed evaluation of body composition, especially fat, muscle and bone mass, and/or their regional distribution, may constitute an important screening test helping to differentiate between highand low-risk endophenotypes of obesity, sarcopenia and osteopenia/osteoporosis. Several methods have been employed for assessing total and regional fat mass in postmenopausal women. 8 Anthropometric variables, such as BMI, waist circumference, waist-to-hip ratio, waist-to-thigh ratio or skinfold thickness, have been widely used in various research or clinical settings; generally, these methods are characterized by limited accuracy and/or are subject to large intra-and inter-observer variability. 8, 9 Various methods, such as underwater weighing and deuterium oxide (D2O) dilution, have been proposed for body composition analysis, but are expensive or else time-consuming, are not patientfriendly and are restricted to research settings. Computed tomography 10 and magnetic resonance imaging (MRI) are currently the "gold standard" methods for the direct measurements of total and regional fat mass; however, their routine use is limited because of inaccessibility to equipment, relatively high cost and, in the case of computed tomography (CT), exposure to ionizing radiation. Dual energy X-ray absorptiometry (DEXA) represents a reliable alternative method of total and regional fat mass estimation because its use offers significant advantages over both CT and MRI, including improved feasibility, lower cost, minimal radiation exposure, high accuracy and reproducibility. 8, 11 Bio-impedance (BIA) devices represent an effective alternative solution to inaccessibility and are likely to prove efficient for fat mass assessment in the clinical setting. BIA-ACC ® is an advanced BIA device that provides quantitative and qualitative information about body composition, including analyses at the molecular and cellular level; 12 the same method reveals associations of body composition parameters via medically unexplained symptoms (MUS) and a Physical Activity Rating (PA-R) questionnaire. 13 This device uses proprietary algorithms for reporting risk factor estimations, such as fat, skeletal muscle and bone mass, intramuscular fat mass, as well as presence of systemic inflammation. [13] [14] [15] BIA-ACC ® is a bloodless, simple, inexpensive and rapid method that does not require skilled staff and, most importantly, does not expose individuals to any radiation.
In this single-gate reproducibility study, we aimed to assess the reliability and agreement between measurements of BIA-ACC ® and DXA; we assessed the BIA-ACC ® device's diagnostic abilities in relation to fat, skeletal muscle and bone mass; finally, we evaluated the clinical significance of MUS and PA-R, as opposed to body composition, in a representative sample of Greek postmenopausal women with or without bone disorders.
METHODS

Procedure
The protocol of this study 16 conformed to the Declaration of Helsinki and was approved by the Institutional Biomedical Research Ethics Committee of the Medical School of the University of Athens. Informed consent was granted by all participants before enrolment in the study.
This study was conducted from October to December 2015. We evaluated participants who presented for DXA bone density assessment at the Endocrine and Bone Metabolic Disorders Unit of the 2nd Department of Internal Medicine of the University of Athens, at the Attikon University Hospital, Athens, Greece. We performed two measurements. First the participants were evaluated by dual energy X-ray absorptiometry (Hologic QDR series Discovery W densitometer of fan beam technology, Hologic, Bedford, MA, USA, provided with software APEX, version 3.2) for bone density assessment (spine, left hip) and whole-body composition scans (whole body DXA scans). Within 5-10 minutes, body composition was also evaluated by using a bio-impedance portable device (BIA-ACC © , BIOTEKNA, Inc., Venice, Italy). The BIA-ACC ® device provides information on total body water, extracellular, intracellular water, fat mass (FM) and fat free mass (FFM) measured both in kilograms (kgs) and as body weight percentage (BW %), bone mass (BM) in kg, skeletal muscle mass (SM) in kgs and as fat free mass percentage (FFM %), etc. (Supplemental Material). Reporting of the study conforms to the GRAAS Statement and the broader EQUATOR guidelines.
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Definitions-Participants-Sampling
Menopause was defined as 12 months of amenorrhea and follicle stimulating hormone serum concentrations >30 U/l. Premature menopause was defined as 12 months of amenorrhea before the age of 40. The T-scores of the bone density measurements, which compare the condition of the individual's bones with those of an average young person with healthy bones, were taken into consideration, as the subject group comprised postmenopausal women. T-scores >-1 were considered normal, -1 to -2.5 defined osteopenia 18 Inclusion criteria included absence of any life-threatening disease (e.g., HIV infection, cancer); presence of any disease that could affect body fat mass; epilepsy; other neurological or severe mental disorders; endocrine or genetic disorders; morbid obesity; or lipodystrophy. Exclusion criteria included presence of metal devices, such as orthopedic prostheses or heart pacemakers, and atopic dermatitis that could cause irritation from skin patches. All women reported a relatively stable body weight (±5%) within the previous 6 months. We used quota sampling to provide a good approximation of the population and to offer better assurance against sampling bias. Moreover, since the parameters of validation in reproducibility studies are influenced by the large (>100) number of participants, we chose to include an adequate number of participants, but not exceedingly large, to scrutinize our results.
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Anthropometry
All anthropometric variables were measured by the same trained physician and operator. Body weight and standing height were measured in light clothing and no shoes using a digital scale with an accuracy of 0.1 kg, and an attached stadiometer (Seca 769; Seca Ltd., Vogel & Halke, Hamburg, Germany) to the nearest 0.1 cm, respectively. BMI was calculated as body weight in kg divided by height in meters squared (Kg/m 2 ), and cut-off points were as set by the World were defined as obese and those with BMI <30 were defined as non-obese.
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DEXA-derived indices
As the reference method, DEXA scan (Hologic QDR series Discovery W densitometer of fan beam technology, Hologic, Bedford, MA, USA, provided with software APEX, version 3.2) was used for the measurement of bone density and of whole and regional body composition estimates, including fat and fat free mass. DEXA provides estimates by measuring the body's absorbance of X-rays at two different energies, given that fat, bone mineral and fat-free soft tissue have different absorption properties. The subjects were positioned for regional and whole-body scans, according to the manufacturer's protocol. Thus, they lay in a supine position on the scanner table with straightened legs and with their arms close to the body. They were instructed to remain as still as possible during the scan. In parallel with bone density, whole-body composition analysis provided data on total FM and its regional (trunk, arms, legs, head) distribution, with an average time of measurement of approximately 7 minutes (QDR bone densitometer with fan-beam technology, software version for Windows XP 12.3, Hologic Discovery-W, Bedford, MA, USA). To ensure proper function of the QDR system daily quality control procedures were performed. We obtained in vitro precision using an appropriate spine phantom of the manufacturer daily and a step phantom on a weekly basis as well. In vivo precision was achieved using repeated measurements after repositioning of the same patient: this was 0.9% for the lumbar spine, 1.1% for total hip, 1.5% for fat %, 1.9% for fat mass and 0.9% for free fat mass.
BIA-derived indices
Bio-impedance body composition analysis was performed using a portable BIA device (BIA-ACC ® , BIOTEKNA, Inc., Venice, Italy) within 5-10 minutes after the DEXA measurement. This device applies alternating currents using two different frequencies, 50 and 1.5 kHz (bi-frequency measurement method), to measure body composition, based on a multicompartment model (2C, 3C, 4C, 5C). 12 The subjects lay supine on an examination bed, while there was no skin contact with metallic elements. Two skin patches-with a horizontal distance of 10 cm between them-were applied on the dorsal surface of the right hand and an additional pair of skin patches on the dorsal surface of the right foot (Hand-to-Foot). The skin patches were connected to the electrodes of the BIA-ACC ® device. The formulas used for computations have been described in detail elsewhere.
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BIA-ACC ® measures additional indices
Immediately before the BIA measurement, the participants were asked to fill in two questionnaires: a MUS close-ended questionnaire inherent in the BIOTEKNA platform program of a personal computer-responding 'yes' or 'no'-and a Physical Activity Rating questionnaire (Supplemental Material). 22 Information about body composition was provided at the quantitative and qualitative molecular, cellular and functional levels. The MUS analyses were presented in a 3-page PDF file. 12 The device uses proprietary algorithms for reporting various body composition risk factors for health, such as BM, FM, intramuscular FM (IMAT) and systemic inflammation (Supplemental Material). 13 Lastly, the BIA-ACC ® device generates reports of a SM index. Sarcopenia was defined by SM index calculations obtained by dividing appendicular SM evaluated by DEXA divided by body height squared (ASM/Ht 2 ), and the percentage of SM index (SMI%=total SM/body mass × 100) defining Class I sarcopenia in females as 19-24% and Class II sarcopenia as below 19% of total body weight. 14, 23, 24 The DEXA and BIA-ACC ® measurements were performed by the same two operators, respectively.
Statistical analyses
For all analyses, p <0.05 was considered statistically significant. The normality of data was assessed with the Shapiro-Wilk test and normal probability plots (Q-Q plots, P-P plots). BIA FM in kgs and as BW % were classified as index tests. We used intraclass correlation co-efficient (ICC) 25 to assess the withinsubjects variance of the FM, either in kgs or in body weight percentage (BW%), Deming regressions 26 to assess the agreement between the measurements of the two methods and Bland-Altman plots to quantify the bias and the range of agreement within which 95% of the differences between the two types of measurement were included. 27 We performed calculations in order to evaluate BIA-ACC ® -determined bone mass as a screening test for abnormal T-score. 28 Pearson's chi squared tests (x 2 ) were used for the evaluation of association between qualitative variables, Pearson's correlation co-efficient to assess the correlations between the quantitative variables and one-way variable analyses (ANOVAs), using Bonferroni correction, and Dunnett's T3 post hoc tests to assess the differences between the quantitative variables. We performed all statistical analyses with SPSS v.21 and MedCalc v.14.
RESULTS
Participants
The selection process is described in Figure 1 and the characteristics of subjects are presented in Table  1 . The study group consisted of 84 postmenopausal women aged 39-83 years, with BMI ranging from 20.8 to 38. Among them, 22 females had normal bone density, 38 were diagnosed with osteopenia The mean values of the estimates by BIA-ACC ® and DEXA devices are presented in Table 2 . Statistically significant differences were found in weight, BMI, DEXA FM in kgs, DEXA FFM in kgs, BIA FM in kgs, BIA IMAT in kgs, BIA SM in kgs, BIA SM as FFM %, BIA-ACC ® BM in kgs and mineral mass of bones as kgs ( Table 2) . Post hoc comparisons revealed that the normal bone density group exhibited increased BIA SM in kgs when compared with the osteopenia (p=0.012) and osteoporosis groups (p=0.003), increased BIA SM as FFM % when compared with the other two groups (p=0.019; p=0.004, respectively), increased BIA BM in kgs (p=0.046; p=0.012, respectively) and increased BIA mineral mass of bones (p=0.046; p=0.012, respectively). Post hoc comparisons of DEXA FFM and FM in kgs revealed increased FM in the normal density group when compared with the osteoporosis group and increased FFM when compared with the other two groups. Lastly, the normal bone density group exhibited increased IMAT when compared to the osteoporosis group. Strong associations were demonstrated between the three groups and the presence of sarcopenia as estimated by BIA-ACC ® and the bone mass as risk factor as estimated by BIA-ACC ® . When the threedimensional group variable (normal bone density group, osteopenia, osteoporosis groups, estimated by DEXA) was transformed into a two-dimensional group variable (Normal T-scores; Abnormal T-scores estimated by DEXA), the strong relation between the bone, as risk factor, and the two-dimensional group variable was verified (x 2 =10.219; df=1; p <0.001; Pearson's contingency co-efficient=0.329; p <0.001).
We also found strong relations between the 2-variable groups (Normal T-scores/Abnormal T-scores) and the presence of sarcopenia (Yes/No) (x 2 =5.476; df=1; p=0.019), the presence of mood disorders (x 2 =5.671; df=1; p=0.017) and feelings of guilt (x 2 =5.255; df=1; p=0.022).
Height of the study participants was negatively correlated with age (r=-0.469; n=84; p <0.001), not only in the total sample but also in the normal bone density group (r=-0.432; n=22; p=0.045), the osteopenia group (r=-0.455; n=38; p=0.004) and the osteoporosis group (r =-0.518; n=24; p=0.01).
Statistically significant correlations were observed between fat mass, muscle mass and bone mass in kgs. In the total sample, bone vs. skeletal muscle mass in kgs (r=0.99; p <0.001) and bone vs. fat mass in kgs (r=0.634; p <0.001) were significantly and strongly correlated. The same trend of strong, statistically significant linear correlation was observed between muscle mass and fat mass in kgs (r=0.652; p <0.001). The corresponding correlations between bone and skeletal muscle mass in kgs in the three groups were strong and statistically significant (Normal bone density group: r=0.991; p <0.001; Osteopenia: r=0.99; p <0.001; Osteoporosis: r=0.983; p <0.001). The correlations between bone and fat mass in kgs were statistically significant in the normal bone density group (r=0.56; p=0.007) and in the osteopenia group (r=0.733; p <0.001) but not in the osteoporosis group.
The same finding was observed in the correlations between fat and skeletal muscle mass (Normal bone density: r=0.549; p=0.008; Osteopenia: r=0.785; p <0.001) (Figure 2 ).
Index Test results
In this study, BIA-ACC ® fat and fat free mass in kgs and as BW% were the index tests. were also acceptable ( Figure 6 ). Bone mass as a risk factor for osteopenia/osteoporosis, determined by the BIA-ACC ® device, proved promising in predicting abnormal T-score presence by DEXA (Table 3) . The ratio of fat mass over skeletal muscle mass was stable in the non-osteoporotic, osteopenic and osteoporotic subjects (Figure 7 ). However, there was a positive correlation of BMI or fat mass with IMAT in all three groups.
DISCUSSION
We found that BIA-ACC ® measurements had high reliability and a relatively strong agreement with DEXA measurements in evaluating body composition variables in a representative sample of postmenopausal women. Our subjects were lean, overweight or obese. Of note, subjects with normal bone density demonstrated increased BMI, FM in kgs and as BW %, by both BIA-ACC ® and DEXA, when compared with the other two groups, indicating a possibly protective role of obesity and increased body weight in osteoporosis development, in accordance with other studies. 29, 30 Increased weight-related changes in body composition, metabolic and hormonal factors or the observed decline in physical activity might provide pathophysiologic mechanisms for populations prone to gain fat mass and lose muscle and bone mass. 31 However, the relation of obesity with osteoporosis has been questioned and several studies have supported an aggravating role of obesity in osteoporosis. [32] [33] [34] [35] Unfortunately, neither DEXA nor BIA-ACC ® could estimate obesity-related qualitative changes of the muscle and bone architecture.
Even though we did not observe any significant differences in height between the three groups studied, height was negatively correlated with age, both in the total group and separately in the study groups. This finding confirmed previous studies. 36 Presence of sarcopenia correlated strongly with the decreased bone density T-score groups in our study. Numerous earlier and recent studies support a "synergistic" role of sarcopenia in the development of osteoporosis, as well as bone fracture incidence. [37] [38] [39] [40] One general major limitation is the lack of definition of sarcopenia. No consensus exists and no task force has as yet defined universally acceptable cut-offs; however, extrapolating from the osteopenia (T-score <1SD -<2.5SD) and osteoporosis (<2.5SD) cut-offs would be a reasonable approach. Interestingly, DEXA operating programs do not include automated results of skeletal muscle mass reports and thus do not provide sarcopenia values. 23 One should note that the formulas used in DEXA for sarcopenia estimation lack accuracy, as sarcopenia is an uneven condition, disturbing mainly postural muscles, while DEXA underestimates limb body mass by up to 20%. 41 Only one study used mathematical predictions of sarcopenia in a sample of an aged population. 42 This was the first prediction model used to identify sarcopenia based on parameters of demographic and functional fitness measures in community-dwelling older adults. Interestingly, Drey at al supported the combined management of decreased bone density together with muscle mass rehabilitation, as sarcopenia is a strong risk factor for falls and bone fractures. 37 We have also observed interesting correlations between fat, skeletal muscle and bone mass in the total sample. These correlations confirm previous studies that have disputed the value of weight loss in postmenopausal women granted that in the absence of physical activity the loss may involve not only fat but skeletal muscle and bone mass. 43, 44 Our findings indicate the negative impact of estrogen decrease not only on bone mass, but also possibly on other Fat mass in kgs to skeletal muscle mass in kgs ratio shown as a marker of concordance between fat and muscle mass and absence of frailty in the three groups. Of note, intramuscular adipose tissue (IMAT) was directly proportional to BMI and fat mass, suggesting poor muscle functioning in the more obese subjects of all three groups. tissues that derive from mesenchymal stem cells, such as the skeletal muscles. 45 Increased fat mass was associated with increased IMAT in our subjects, suggesting suboptimal skeletal muscle functioning in the more obese individuals. As previously reported, elevated inflammatory adipocytokine secretion by increased fat mass is associated with the chronic mild "smoldering" systemic inflammation that is always associated with obesity. 15 Most of our subjects exhibited low adherence to physical activity. This finding is similar to that of a previous observational study performed in the Attica prefecture, Greece, in 2005. 46 It may also be the reason behind the high prevalence of sarcopenia given that physical activity is a very important component in the management of patients with body weight problems and bone metabolic disorders.
MUS and feelings of guilt were increased in the groups with decreased T-scores and demonstrated no relation with age or BMI. MUS are physical symptoms whose presence, severity or consequences cannot be conclusively explained by any detectable physical disorder. MUS are more prevalent in females than males, in younger than in older subjects and in the currently employed than in the non-employed. 47 MUS are quite common in later life; however, the available data suggest that the prevalence rate declines after the age of 65 years. 48 These apparently contradictory results might be due to the lack of a consensus in the definition of MUS, which fall into the category of somatomorphic disorders, as well as the paucity of guidelines of MUS definition and management. 49 Estimates of prevalence inevitably vary with definition, but are higher in patients seen at primary care doctor's offices, with these physicians having more confidence in their ability to diagnose and manage mental health problems. Feelings of guilt are associated with other depressive symptomatology, 50 while recent studies have associated depression with bone fracture risk and mental health. [51] [52] [53] Our BIA-ACC ® platform results of the MUS questionnaire confirmed the aforementioned studies and provided an easy, reliable screening test in postmenopausal women (supplementary information).
DEXA has been employed as the "gold standard" method for body composition analysis. BIA-ACC ® has the advantage over DEXA of avoiding radiation exposure. One strength of our study is the use of the two methods in conjunction to assess the reliability and agreement between them and not just to compare them by means of one statistical test, as a recent systematic review has suggested. 28 The BIA-ACC ® method has shown consistent repeatability in postmenopausal women.
There are limitations of our study. First, we did include the fat free mass of the BIA device in the indices tests. In BIA equations, since fat and fat free mass equals 1, 13 it would be considered redundant. As mentioned earlier, DEXA possibly underestimates fat free mass, 41 while skeletal muscle mass biopsies are considered too invasive for research settings. We found that intramuscular adipose tissue infiltration correlated with BMI and total adipose tissue mass, suggesting muscular degeneration in the more obese subjects, regardless of their muscle and bone mass. Lastly, we did not administer any psychometric questionnaire for stress, anxiety or depression in our subjects.
The acceptance and potential applications of diagnostic point-of-care testing (POC) in resource-limited settings, such as private practice offices, have been developing rapidly and are likely to continue growing. The goal of the introduction of new POC tests and POC devices is to provide fast, affordable test results to clinicians so that they may make an expedited clinical management decision and hence improve patient outcomes and overall public health. [54] [55] [56] The BIA-ACC ® device offers an acceptable determination of body composition with a satisfactory variability and with demonstration of a strong concordance with the traditional DEXA reference standard in postmenopausal women. It also provides information about sarcopenia and serves as a safe screening tool for abnormal bone density. Thus, this device provides screening and monitoring evaluations that are important in the management of subjects with chronic fat, muscle and bone metabolic disorders.
Future studies should be performed to validate the diagnostic potential of BIA-ACC ® devices in other age and gender groups and in subjects with pathologies affecting fat, muscle and bone mass.
